Invention Grant
- Patent Title: Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
-
Application No.: US17680719Application Date: 2022-02-25
-
Publication No.: US11759518B2Publication Date: 2023-09-19
- Inventor: Tomoya Miyakawa , Shun Doi , Koji Tamada
- Applicant: NEC CORPORATION
- Applicant Address: JP Tokyo
- Assignee: NEC CORPORATION
- Current Assignee: NEC CORPORATION
- Current Assignee Address: JP Tokyo
- Agency: Sughrue Mion, PLLC
- Priority: JP 16200227 2016.10.11
- The original application number of the division: US16341415
- Main IPC: C07K7/06
- IPC: C07K7/06 ; C07K14/705 ; C07K19/00 ; A61K39/39 ; A61K31/739 ; A61K38/08 ; A61K38/17 ; A61P35/00 ; A61K39/00 ; A61K31/7088
Abstract:
The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.
Public/Granted literature
- US20220175915A1 MEDICINE FOR TREATING CANCER BY ADMINISTERING A TOLL-LIKE RECEPTOR AGONIST AND LAG-3 IgG FUSION PROTEIN Public/Granted day:2022-06-09
Information query
